+

WO2004080379A3 - Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique - Google Patents

Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique Download PDF

Info

Publication number
WO2004080379A3
WO2004080379A3 PCT/FR2004/000504 FR2004000504W WO2004080379A3 WO 2004080379 A3 WO2004080379 A3 WO 2004080379A3 FR 2004000504 W FR2004000504 W FR 2004000504W WO 2004080379 A3 WO2004080379 A3 WO 2004080379A3
Authority
WO
WIPO (PCT)
Prior art keywords
antinecrotic
lignanes
effect
extract
cathepsin inhibitor
Prior art date
Application number
PCT/FR2004/000504
Other languages
English (en)
Other versions
WO2004080379A2 (fr
Inventor
Daniel Jean
Cherif Rabhi
Veronique Schwaab
Original Assignee
Lmd
Daniel Jean
Cherif Rabhi
Veronique Schwaab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lmd, Daniel Jean, Cherif Rabhi, Veronique Schwaab filed Critical Lmd
Publication of WO2004080379A2 publication Critical patent/WO2004080379A2/fr
Publication of WO2004080379A3 publication Critical patent/WO2004080379A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/742—Organic compounds containing oxygen
    • A23B2/746—Organic compounds containing oxygen with singly-bound oxygen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/771—Organic compounds containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne les extraits de Pangium edule, avantageusement de graines, et les lignanes de formule I. Elle concerne également leur utilisation en tant que médicament inhibiteur de cathepsines ou ayant une action anti-nécrotique.
PCT/FR2004/000504 2003-03-03 2004-03-03 Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique WO2004080379A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0302584A FR2851919A1 (fr) 2003-03-03 2003-03-03 Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
FR03/02584 2003-03-03

Publications (2)

Publication Number Publication Date
WO2004080379A2 WO2004080379A2 (fr) 2004-09-23
WO2004080379A3 true WO2004080379A3 (fr) 2004-10-28

Family

ID=32865199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000504 WO2004080379A2 (fr) 2003-03-03 2004-03-03 Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique

Country Status (2)

Country Link
FR (1) FR2851919A1 (fr)
WO (1) WO2004080379A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5131855B2 (ja) * 2006-03-02 2013-01-30 学校法人日本大学 植物由来の悪性腫瘍治療薬
US9145534B2 (en) 2006-07-28 2015-09-29 Bioriginal Food & Science Corporation Fat containing composition
EP2462946B1 (fr) * 2006-08-16 2014-07-09 National Research Council of Canada Procédé d'inhibition de l'activité de la cathepsine
CN101805325A (zh) * 2009-02-17 2010-08-18 中国科学院成都生物研究所 一种新木酚素化合物及其用途
CN109734696B (zh) * 2018-10-29 2021-03-30 江西省药品检验检测研究院 一种新的二环氧木脂素化合物及其制备方法
CN112250689B (zh) * 2019-11-07 2022-01-18 江苏新元素医药科技有限公司 具有肝病疗效的化合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2035300A (en) * 1978-09-16 1980-06-18 Madaus & Co Dr Americanin
EP0159565A1 (fr) * 1984-04-02 1985-10-30 Merck & Co. Inc. Dérivés substitués de 2,3,3 alpha,6-tétrahydro-6-oxabenzofuranne utiles comme antagonistes de PAF
JPS6399011A (ja) * 1986-04-30 1988-04-30 Otsuka Pharmaceut Co Ltd プロスタグランデインｉ↓２生成亢進剤
JPS63167791A (ja) * 1986-12-27 1988-07-11 Kanebo Ltd 突然変異抑制剤
WO2000059946A1 (fr) * 1999-03-30 2000-10-12 Hormos Nutraceutical Oy Ltd Hydroxymatairesinol en prevention anti-cancereuse
WO2002047706A2 (fr) * 2000-12-15 2002-06-20 Pharmacia Corporation Inhibition sélective de la cox-2 au moyen d'extraits végétaux
WO2002080702A1 (fr) * 2001-04-04 2002-10-17 Unilever N.V. Utilisation de lignans dans des aliments
US6489514B1 (en) * 2001-07-27 2002-12-03 Council Of Scientific And Industrial Research (-)-Secoisolariciresinol as an antioxidant obtained from a new natural source namely stereospermum personatum

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2035300A (en) * 1978-09-16 1980-06-18 Madaus & Co Dr Americanin
EP0159565A1 (fr) * 1984-04-02 1985-10-30 Merck & Co. Inc. Dérivés substitués de 2,3,3 alpha,6-tétrahydro-6-oxabenzofuranne utiles comme antagonistes de PAF
JPS6399011A (ja) * 1986-04-30 1988-04-30 Otsuka Pharmaceut Co Ltd プロスタグランデインｉ↓２生成亢進剤
JPS63167791A (ja) * 1986-12-27 1988-07-11 Kanebo Ltd 突然変異抑制剤
WO2000059946A1 (fr) * 1999-03-30 2000-10-12 Hormos Nutraceutical Oy Ltd Hydroxymatairesinol en prevention anti-cancereuse
WO2002047706A2 (fr) * 2000-12-15 2002-06-20 Pharmacia Corporation Inhibition sélective de la cox-2 au moyen d'extraits végétaux
WO2002080702A1 (fr) * 2001-04-04 2002-10-17 Unilever N.V. Utilisation de lignans dans des aliments
US6489514B1 (en) * 2001-07-27 2002-12-03 Council Of Scientific And Industrial Research (-)-Secoisolariciresinol as an antioxidant obtained from a new natural source namely stereospermum personatum

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANDARWULAN N ET AL: "Antioxidant Activity Associated with Lipid and Phenolic Mobilization during Seed Germination of Pangium edule Reinw", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, no. 8, 1999, pages 3158 - 3163, XP002252812, ISSN: 0021-8561 *
CHAKRABARTY T ET AL: "THE FLACOURTIACEAE OF ANDAMAN-NICOBAR ISLANDS", JOURNAL OF ECONOMIC AND TAXONOMIC BOTANY, SCIENTIFIC PUBLISHERS, JODHPUR,, IN, vol. 16, no. 3, 1992, pages 715 - 722, XP009034072, ISSN: 0250-9768 *
DATABASE WPI Section Ch Week 198833, Derwent World Patents Index; Class B05, AN 1988-232627 *
FORD J D ET AL: "PLANT LIGNANS AND HEALTH: CANCER CHEMOPREVENTION AND BIOTECHNOLOGICAL OPPORTUNITIES", PLANT POLYPHENOLS 2: CHEMISTRY, BIOLOGY, PHARMACOLOGY, ECOLOGY, XX, XX, 1999, pages 675 - 694, XP002933628 *
GU WENXIN ET AL: "First asymmetric synthesis of chiral 1,4-benzodioxane lignans", TETRAHEDRON LETTERS, vol. 41, no. 32, 5 August 2000 (2000-08-05), pages 6079 - 6082, XP002261880, ISSN: 0040-4039 *
HARAGUCHI H ET AL: "INHIBITION OF MONOAMINE OXIDASE BY EXTRACTS OF SOUTHEAST ASIAN PLANTS", NATURAL MEDICINES - SHOYAKUGAKU ZASSHI, JAPANESE SOCIETY OF PHARMACOGNOSY, TOKYO, JP, vol. 57, no. 5, October 2003 (2003-10-01), pages 196 - 199, XP009034070, ISSN: 1340-3443 *
MATSUMOTO KEIJI ET AL: "Convenient syntheses of neurotrophic americanol A and isoamericanol A by HRP catalyzed oxidative coupling of caffeic acid", TETRAHEDRON LETTERS, vol. 40, no. 16, 16 April 1999 (1999-04-16), pages 3185 - 3186, XP002261879, ISSN: 0040-4039 *
NAKATSUBO, FUMIAKI ET AL: "Enzymic dehydrogenation of p-coumaryl alcohol. II. Configuration of phenylcoumarans", HOLZFORSCHUNG , 29(3), 95-8 CODEN: HOLZAZ; ISSN: 0018-3830, 1975, XP009035758 *
PATENT ABSTRACTS OF JAPAN vol. 0123, no. 38 (C - 527) 12 September 1988 (1988-09-12) *
SHE, XUEGONG ET AL: "A Convenient Synthesis of (.+-.)-3-Methoxybenzodioxane-4,9,9'-triol Neolignan, and Methyl Ethers of Isoamericanol A and Isoamericanin A", JOURNAL OF CHEMICAL RESEARCH, SYNOPSES , (2), 100-101 CODEN: JRPSDC; ISSN: 0308-2342, 1999, XP009035710 *
WOO, WON SICK ET AL: "The structure of new lignans from the seeds of Phytolacca americana", TETRAHEDRON LETTERS , 21(44), 4255-8 CODEN: TELEAY; ISSN: 0040-4039, 1980, XP002294350 *
YOSHIHARA, TERUHIKO ET AL: "Phenolic compounds from the roots of Solanaceae plants. Part III. The relative configuration of grossamide and hordatines", AGRICULTURAL AND BIOLOGICAL CHEMISTRY , 47(2), 217-20 CODEN: ABCHA6; ISSN: 0002-1369, 1983, XP009035753 *
YU, JINGGUANG ET AL: "Neo-lignans and hemiterpenoid from the seeds of Artabostrys hexapetalus (Annonaceae)", JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES , 11(1), 4-10 CODEN: JCHSE4; ISSN: 1003-1057, 2002, XP001183343 *

Also Published As

Publication number Publication date
FR2851919A1 (fr) 2004-09-10
WO2004080379A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2007120980A3 (fr) Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
WO2001068092A3 (fr) Inhibiteur de glycogene phosphorylase
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
WO2008009379A3 (fr) Associations de principes actifs présentant des propriétés insecticides et acaricides
WO2006073457A8 (fr) Composes bioactifs et procedes de leur utilisation
WO2002066450A3 (fr) Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones et derives de ceux-ci en tant qu'inhibiteur de jnk, ainsi que compositions et procedes associes
IL174536A (en) Combination comprising candesartan and rosuvastatin, pharmaceutical compositions comprising such combination and use of such combination as a medicament for the prevention or treatment of atherosclerosis or cardiovascular events
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
WO2005002423A3 (fr) Sonde helicoidale
WO2005051083A3 (fr) Composes molluscicides et anti-anatifes
WO2004084842A3 (fr) Inhibiteurs de cathepsine s
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2004080379A3 (fr) Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique
WO2005042021A3 (fr) Composition pharmaceutique contenant un agoniste des recepteurs beta-3-adrenergiques et un antagoniste alpha et/ou un inhibiteur de la 5-alpha-reductase
WO2004087045A3 (fr) Dispositifs, methodes et compositions permettant de prevenir la restenose
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2002022150A3 (fr) Medicament contenant de l'antithrombine iii activee
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
WO2004056832A3 (fr) Derives d'epothilone
AU2001281613A1 (en) Extracts from the fungus guignardia sp., their uses in pharmaceutical compositions, new isolate compound from the extract of the fungus guignardia sp. and its use in pharmaceutical compositions
WO2006020244A3 (fr) Compositions et méthodes associées à l'insuffisance cardiaque
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载